Vanadium and blood sugar
What 5 graded rows on vanadium agree on for blood sugar, and where they differ. Counted side by side, never averaged.
Consensus finder Rows from the Vanadium page, reviewed Oct 21, 2026 How it decides
What the rows agree on
Each block and row is one graded row from the Vanadium page, with its PubMed record.
Your question
Vanadium and blood sugar
5 rows · 85 peopleMostly an improvement: 4 of 5 rows, and most of the people. 1 had mixed results.
- DGrade D× 5
- Rows
- 5
- Trials
- 5
- People
- 85
What the rows share
From the rowsThe best-graded row, grade D, is a randomized trial of 44 people (2023) and found an improvement.
The rows run from 6 to 44 people, published from 1995 to 2023: 5 single studies.
The rows
4 improved · 1 mixed- DGrade DBlood sugar, insulin sensitivity and body measurements in type 2 diabetes · Improved
RCT · n 44 · 2023 · Adults with obesity and type 2 diabetes (Iran)
0.9 mg/day vanadium pentoxide · 12 weeks
After adjustment for covariates, glycemic measures and body measurements fell and insulin sensitivity rose versus placebo; lipids, diet and quality of life did not change.
- DGrade DBlood sugar control in type 2 diabetes · Improved
Open-label trial · n 11 · 2001 · Adults with type 2 diabetes
150 mg/day · 6 weeks
Fasting glucose fell from 194 to 155 mg/dL and HbA1c from 8.1% to 7.6%, with no change in body weight; total and LDL cholesterol also fell, and 24-hour blood pressure did not change.
- DGrade DFasting glucose and liver insulin resistance in type 2 diabetes · Improved
Open-label trial · n 8 · 1996 · Adults with type 2 diabetes (4 men, 4 women)
50 mg twice daily · 4 weeks, then 4 weeks of placebo in 6 participants
Fasting glucose fell about 20% (9.3 to 7.4 mmol/L) and liver glucose output during insulin infusion dropped; whole-body glucose uptake did not change. Six of eight had gut side effects in the first week.
- DGrade DBlood sugar and insulin sensitivity in type 2 diabetes · Improved
Open-label trial · n 6 · 1995 · Adults with type 2 diabetes on diet and/or sulfonylureas
100 mg/day · 3 weeks, between two 2-week placebo periods
Fasting glucose fell from 210 to 181 mg/dL and HbA1c from 9.6% to 8.8%; insulin-stimulated glucose uptake during a clamp rose by about 88%, and the effect lasted through the 2-week placebo period afterwards.
- DGrade DInsulin sensitivity and blood sugar at three doses · Mixed
Open-label trial · n 16 · 2000 · Adults with type 2 diabetes
75, 150 or 300 mg/day · 6 weeks
No improvement at 75 mg/day. Fasting glucose and HbA1c fell at 150 and 300 mg/day, but clamp-measured insulin sensitivity improved in only some participants; the authors concluded tolerated doses do not dramatically improve glycemic control.